Overview of management of narcolepsy

Narcolepsy: A Clinical Guide

Volumn , Issue , 2010, Pages 251-265

  Nishino, Seiji ^a   Kotorii, Nozomu ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amphetamine; Antidepressants; Cataplexy; Gamma hydroxybutyrate; Hypnogogic hallucinations; Modafinil; Narcolepsy; Sleep paralysis; Stimulants

Indexed keywords

EID: 80755144904     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-0854-4_23     Document Type: Chapter

References (117)

1. Hublin C, Kaprio J, Partinene M, et al. The prevalence of narcolepsy: an epidemiological study of the Finnish twin cohort. Ann Neurol 1994;35:709-16.
2. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998;50(suppl 1):S16-S22.
3. ICSD-2, ed. ICSD-2-International classifcation of sleep disorders, 2nd ed.:. Diagnostic and coding manual. Westchester, Illinois: American Academy of Sleep Medicine 2005.
4. Beusterien KM, Rogers AE, Walsleben JA, et al. Health-related quality of life effects of modafnil for treatment of narcolepsy. Sleep 1999;22(6):757-65.
5. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebro-spinal fuid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59(10): 1553-62.
6. Nishino S, Kanbayashi T. Symptomatic narcolepsy, cata-plexy and hypersomnia, and their implications In the hypo-thalamic hypocretin/orexin system. Sleep Med Rev 2005;9(4):269-310.
7. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997;52(1):27-78.
8. Honda Y. Clinical features of narcolepsy: Japanese experience. In: Honda Y, Juji T, eds. HLA in narcolepsy. New York: Springer-Verlag; 1988:24-57.
9. Rogers AE. Problems and coping strategies identifed by nar-coleptic patients. J Neurosurg Nursing 1984;16(6):326-34.
10. Roehrs T, Zorick F, Wittig R, Paxton C, Sicklesteel J, Roth T. Alerting effects of naps in patients with narcolepsy. Sleep 1986;9(1):194-9.
11. Garma L, Marchand F. Non-pharmacological approaches to the treatment of narcolepsy. Sleep 1994;17:S97-S102.
12. Association AN. Stimulant medication survey. Eye Opener 1992:1-3.
13. Kuczenski R, Segal DS, Cho AK, Melega W. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 1995;15(2):1308-17.
14. Snyder SH, Taylor KM, Coyle JT, Meyerhoff JL. The role of brain dopamine in behavioral regulation and the actions of psychotropic drugs. Am J Psychiatry 1970;127(2):199-207.
15. Mitler MM, Aldrich MS, Koob GF, Zarcone VP. Narcolepsy and its treatment with stimulants. ASDA standards of practice. Sleep 1994;17(4):352-71.
16. Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007;30(12):1705-11.
17. Mitler MM, Hajdukovic R. Relative effcacy of drugs for the treatment of sleepiness in narcolepsy. Sleep 1991;14(3): 218-20.
18. Simpson LL. Blood pressure and heart rate responses produced by D-amphetamine: correlation with blood levels of drug. J Pharmacol Exp Ther 1978;205(2):366-73.
19. Akimoto H, Honda Y, Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Syst 1960;21:704-6.
20. Parkes JD, Baraitser M, Marsden CD, Asselman P. Natural history, symptoms and treatment of the narcoleptic syndrome. Acta Neurol Scand 1975;52:337-53.
21. Guilleminault C, Carskadon M, Dement WC. On the treatment of rapid eye movement narcolepsy. Arch Neurol 1974;30:90-3.
22. Passouant P, Billiard M. The evolution of narcolepsy with age. In: Guilleminault C, Dement WC, Passouant P, eds. Narcolepsy. New York: Spectrum; 1976:179-86.
23. Rogers AE, Aldrich MS, Berrios AM, Rosenberg RS. Compliance with stimulant medications in patients with narcolepsy. Sleep 1997;20(1):28-33.
24. Prinzmetal M, Bloomberg W. The use of benzedrine for the treatment of narcolepsy. J Am Med Assoc 1935;105:2051-4.
25. Alles GA. The comparative physiological actions of d 1-beta- phenylisopropylamines: pressor effects and toxicity. J Pharmacol Exp Ther 1933;47:339-54.
26. Parkes JD, Fenton GW. Levo(-) amphetamine and dextro(+) amphetamine in the treatment of narcolepsy. J Neurol Neurosurg Psychiatry 1973;36(6):1076-81.
27. Parkes D. Amphetamines and other drugs. In: Sleep and its disorders. London: W.B. Saunders Company; 1985:459-82.
28. Parkes D. Amphetamines and alertness. In: Guilleminault C, Dement WC, Passouant P, eds. Narcolepsy. New York: Spectrum; 1976:643-58.
29. Williams RT, Caldwell RJ, Dreng LG. Comparative metabolism of some amphetamine in various species. In: Schneider SH, Esdin E, eds. Frontiers of catecholamine research. Oxford, England: Pergamon; 1973:927-32.
30. Beckett AH, Rowland M, Turner P. Infuence of urinary Ph on excretion of amphetamine. Lancet 1965;1(7380):303.
31. Yoss RE, Daly D. Treatment of narcolepsy with ritalin. Neurology 1959;9(3):171-3.
32. Pawluk LK, Hurwitz TD, Schluter JL, Ullevig C, Mahowald MW. Psychiatric morbidity in narcoleptics on chronic high dose methylphenidate therapy. J Nerv Ment Dis 1995;183(1): 45-8.
33. Goenechea S, Wagner GM. [Quantitative determination of pemoline in serum and urine after ingestion of therapeutic doses (author's transl)]. Arzneimittelforschung 1977;27(8): 1604-5.
34. Berkovitch M, Pope E, Phillips J, Koren G. Pemoline-associated fulminant liver failure: testing the evidence for causation. Clin Pharmacol Ther 1995;57(6):696-8.
35. Shevell M, Schreiber R. Pemoline-associated hepatic failure: a critical analysis of the literature. Pediatr Neurol 1997;16(1):14-6.
36. Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafnil. Prog Neuropsychopharmacol Biol Psychiatry 1988;12(5): 695-700.
37. Besset A, Tafti M, Villemin E, Billiard M. [The effects of modafnil (300mg) on sleep, sleepiness and arousal in narco-leptic patients]. Neurophysiol Clin 1993;23(1):47-60.
38. Boivin DB, Montplaisir J, Petit D, Lambert C, Lubin S. Effects of modafnil on symptomatology of human narcolepsy. Clin Neuropharmacol 1993;16(1):46-53.
39. Randomized trial of modafnil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafnil in Narcolepsy Multicenter Study Group. Neurology 2000;54(5): 1166-75.
40. Broughton RJ, Fleming JA, George CF, et al. Randomized, double-blind, placebo-controlled crossover trial of modafnil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997;49(2):444-51.
41. Wong YN, King SP, Laughton WB, McCormick GC, Grebow PE. Single-dose pharmacokinetics of modafnil and methylphenidate given alone or in combination in healthy male volunteers. J Clin Pharmacol 1998;38(3):276-82.
42. Wong YN, Simcoe D, Hartman LN, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the phar-macokinetics and tolerability of modafnil tablets in healthy male volunteers. J Clin Pharmacol 1999;39(1):30-40.
43. Wong YN, King SP, Simcoe D, et al. Open-label, single-dose pharmacokinetic study of modafnil tablets: infuence of age and gender in normal subjects. J Clin Pharmacol 1999;39(3):281-8.
44. Robertson P, Jr., Hellriegel ET. Clinical pharmacokinetic pro-fle of modafnil. Clin Pharmacokinet 2003;42(2): 123-37.
45. Hermant JF, Rambert FA, Deuteil J. Lack of cardiovascular effects after administration of modafnil in conscious monkeys. In: French Association des Pharmacologistes Tours, 1991: Fundam Clin Pharmacol; 1991:825.
46. Gold LH, Balster RL. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafnil. Psychopharmacology (Berl) 1996;126(4): 286-92.
47. Edgar DM, Seidel WF, Contreras P, Vaught JL, Dement WC. Modafnil promotes EEG wake without intensifying motor activity in the rat. Can J Physiol Pharmacol 1994; 72(S1):362.
48. Harsh JR, Hayduk R, Rosenberg R, et al. The effcacy and safety of armodafnil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006;22(4):761-74.
49. Iijima S, Sugita Y, Teshima Y, Hishikawa Y. Therapeutic effects of mazindol on narcolepsy. Sleep 1986;9(1, Part 2):265-8.
50. Nishino S, Mao J, Sampathkumaran R, Shelton J. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online 1998;1(1): 49-61.
51. Hadler AJ. Mazindol, a new non-amphetamine anorexigenic agent. J Clin Pharmacol New Drugs 1972;12(11):453-8.
52. Nishino S, Mao J, Sampathkumaran R, Shelton J, Mignot E. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Research Online 1998;1:49-61. http://www.sro.org/1998/Nishino/49/.
53. Rye DB, Dihenia B, Bliwise DL. Reversal of atypical depression, sleepiness, and REM-sleep propensity in narcolepsy with bupropion. Depress Anxiety 1998;7(2):92-5.
54. Sicard BA, Perault MC, Enslen M, Chauffard F, Vandel B, Tachon P. The effects of 600 mg of slow release caffeine on mood and alertness. Aviat Space Environ Med 1996;67(9): 859-62.
55. Rall TR. Central nervous system stimulants. In: Gilman AG, Goodman LS, Rall TW, Murad F, eds. The pharmacological basis of therapeutics, 7th Ed. New York: Pergamon; 1985:345-82.
56. Thorpy MJ, Snyder M, Aloe FS, Ledereich PS, Starz KE. Short-term triazolam use improves nocturnal sleep of narco-leptics. Sleep 1992;15(3):212-6.
57. Scrima L, Johnson FH, Thomas EG, Hiller EE. The effects of gamma-hydroxybutyrate (GHB) on multiple sleep latency test (MSLT) in narcolepsy patients; a long term study. Sleep Res 1990;19:288.
58. Scrima L, Hartman PG, Johnson FH Jr, Hiller FC. Effcacy of gamma-hydroxybutyrate versus placebo in treating narco-lepsy-cataplexy: double-blind subjective measures. Biol Psychiatry 1989;26(4):331-43.
59. Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. Can J Neurol Sci 1979;6(1):1-6.
60. Broughton R, Mamelak M. Gamma-hydroxybutyrate in the treatment of compound narcolepsy: a preliminary report. In: Guilleminault C, Dement WC, Passouant P, eds. Narcolepsy. New York: Spectrum; 1976:59-67.
61. Group UXMS. Sodium oxybate demonstrates long-term effcacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5(2):119-23.
62. Group UXMS. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003;26(1):31-5.
63. Group USXMS. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25(1):42-9.
64. Group UXMS. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005;1(4):391-7.
65. Chin MY, Kreutzer RA, Dyer JE. Acute poisoning from gamma-hydroxybutyrate in California. West J Med 1992; 156(4):380-4.
66. Mack RB. Love potion number 8 1/2. Gamma-hydroxybutyrate poisoning. N C Med J 1993;54(5):232-3.
67. Bedard MA, Montplaisir J, Godbout R, Lapierre O. Nocturnal gamma-hydroxybutyrate. Effect on periodic leg movements and sleep organization of narcoleptic patients. Clin Neuropharmacol 1989;12(1):29-36.
68. Wong CG, Gibson KM, Snead OC III. From the street to the brain: neurobiology of the recreational drug gamma-hydroxy-butyric acid. Trends Pharmacol Sci 2004;25(1): 29-34.
69. Nicholson KL, Balster RL. GHB: a new and novel drug of abuse. Drug Alcohol Depend 2001;63(1):1-22.
70. Palatini P, Tedeschi L, Frison G, et al. Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol 1993;45(4): 353-6.
71. Vickers MD. Gammahydroxybutyric acid. Int Anesthesiol Clin 1969;7(1):75-89.
72. Lavie P, Peled R. Narcolepsy is a rare disease in Israel. Sleep 1987;10(6):608-9.
73. Li J, Stokes SA, Woeckener A. A tale of novel intoxication: seven cases of gamma-hydroxybutyric acid overdose. Ann Emerg Med 1998;31(6):723-8.
74. Group UXMS. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms. J Toxicol Clin Toxicol 2003;41(2): 131-5.
75. Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001;37(2):147-53.
76. Perez E, Chu J, Bania T. Seven days of gamma-hydroxybu-tyrate (GHB) use produces severe withdrawal. Ann Emerg Med 2006;48(2):219-20.
77. Henry GK, Hart RP, Kwentus JA, Sicola MJ. Effects of pro-triptyline on vigilance and information processing in narcolepsy. Psychopharmacology (Berl) 1988;95(1):109-12.
78. Raynal D. Polygraphic aspects of narcolepsy. In: Guilemminault C, Dement WC, Passouant P, eds. Narcolepsy. New York: Spectrum; 1976:669-84.
79. Thorpy MJ, Goswami M. Treatment of narcolepsy. In: Thorpy MJ, ed. Handbook of sleep disorders. New York: Marcel Dekker; 1990:235-58.
80. Baldessarini RJ. How do antidepressants work? In: Davis JM, Mass JW, eds. The affective disorders. Wachington, DC: American Psychiatric Press; 1983:243-60.
81. Langdon N, Shindler J, Parkes JD, Bandak S. Fluoxetine in the treatment of cataplexy. Sleep 1986;9(2):371-3.
82. Montplaisir J, Godbout R. Serotoninergic reuptake mechanisms in the control of cataplexy. Sleep 1986;9(1, Part 2):280-4.
83. Schrader H, Kayed K, Bendixen Markset AC, Treidene HE. The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo. Acta Neurol Scand 1986;74(4):297-303.
84. Mignot E, Renaud A, Nishino S, Arrigoni J, Guilleminault C, Dement WC. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psycho pharmacology (Berl) 1993;113(1):76-82.
85. Nishino S, Arrigoni J, Shelton J, Dement WC, Mignot E. Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep 1993;16(8):706-12.
86. Takahashi S. The action of tricyclics (alone or in combination with methylphenidate) upon several symptoms of narcolepsy. In: Guilleminault C, Dement WC, Passouant P, eds. Narcolepsy. New York: Spectrum Publication; 1976:625-38.
87. Koran LM, Raghavan S. Fluoxetine for isolated sleep paralysis. Psychosomatics 1993;34(2):184-7.
88. Mamelak M, Scharf MB, Woods M. Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory fndings. Sleep 1986;9(1, Part 2):285-9.
89. Fujiki N, Ripley B, Yoshida Y, Mignot E, Nishino S. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin recep-tor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin ligand defcient narco-leptic dog. Sleep 2003;6(8):953-9.
90. Schatzberg SJ, Barrett J, Cutter Kl, Ling L, Mignot E. Case study: effect of hypocretin replacement therapy in a 3-year-old Weimaraner with narcolepsy. J Ve t Int Med 2004;18(4):586-8.
91. Mieda M, Willie JT, Hara J, Sinton CM, Sakurai T, Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci USA 2004;101(13):4649-54.
92. Mishima K, Fujiki N, Yoshida Y, et al. Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand defcient human narcolepsy. Sleep 2008;31(8):1119-26.
93. Ripley B, Fujiki N, Okura M, Mignot E, Nishino S. Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis 2001;8(3):525-34.
94. Nishino S, Sakurai E, Nevsimalova A, Yoshida Y, Watanabe T, Yanai K, Mignot E. Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. SLEEP 2009;32(2):175-180.
95. Kanbayashi T, Kodama T, Kondo H, Satoh S, Inoue Y, Chiba S, Shimizu T, Nishino S. CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. SLEEP 2009;32(2):181-187.
96. Kanbayashi T, Kodama T, Hondo H, et al. CSF histamine and noradrenaline contents in narcolepsy and other sleep disorders. Sleep 2004;27(abstract supplement):A236.
97. Lin JS, Sakai K, Vanni-Mercier G, et al. Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat. Brain Res 1990;523(2):325-30.
98. Shiba T, Fujiki N, Wisor J, Edgar D, Sakurai T, Nishino S. Wake promoting effects of thioperamide, a histamine H3 antagonist in orexin/ataxin-3 narcoleptic mice. Sleep 2004;27 (suppl):A241-A242.
99. Parmentier R, Anaclet C, Guhennec C, et al. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem Pharmacol 2007;73(8): 1157-71.
100. Sharif NA, To ZP, Whiting RL. Analogs of thyrotropin-releasing hormone (TRH): receptor affnities in brain, spinal cords, and pituitaries of different species. Neurochem Res 1991;16:95-103.
101. Riehl J, Honda K, Kwan M, Hong J, Mignot E, Nishino S. Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy. Neuropsychopharmacology 2000;23(1):34-45.
102. Nishino S, Arrigoni J, Shelton J, et al. Effects of thyrotro-pin- releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci 1997;17:6401-8.
103. Nicoll RA. Excitatory action of TRH on spinal motoneu-rons. Nature 1977;265:242-3.
104. Sharp T, Bennett GW, Marsden CA. Thyrotropin-releasing hormone analogues increase dopamine release from slices of rat brain. J Neurochem 1982;39:1763-6.
105. Keller HH, Bartholini G, Pletscher A. Enhancement of cerebral noradrenaline turnover by thyrotropin-releasing hormone. Nature 1974;248:528-9.
106. Heuer H, Schafer MK, O'Donnell D, Walker P, Bauer K. Expression of thyrotropin-releasing hormone receptor 2 (TRH-R2) in the central nervous system of rats. J Comp Neurol 2000;428(2):319-36.
107. Broberger C, McCormick DA. Excitatory effects of thy-rotropin releasing hormone in the thalamus. J Neurosci 2005;25:1664-1673.
108. Hara J, Gerashchenko D, Wisor JP, Sakurai T, Xie S, Kilduff TS. Thyrotropin-releasing hormone increases behavioral arousal through modulation of hypocretin/orexin. J Neurosci 2009; 29(12):3705-3714.
109. Parmentier R, Kolbaev S, Klyuch BP, Vandael D, Lin JS, Selbach O, Haas HL, Sergeeva OA, Excitation of Histaminergic tuberomamillary neurons by thyrotropin-releasing hormone. J Neurosci 2009; 29(14):4471-4483.
110. Broberger C. Neurotransmitters switching the thalamus between sleep and arousal: functional effects and cellular mechanism. In: Showa University International Symposium for Life Science 1st Annual Meeting New Frontiers in Neuroscience Research, August 31, 2004, Showa University Kamijo Hall, Tokyo.
111. Okura M, Riehl J, Mignot E, Nishino S. Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy. Neuropsychopharmacology 2000;23(5):528-38.
112. Bergstrom DL, Keller C. Narcolepsy: pathogenesis and nursing care. J Neurosci Nurs 1992;24(3):153-7.
113. Parkes JD, Dahlitz M. Amphetamine prescription. Sleep 1993;16:201-3.
114. Guilleminault C, Stoohs R, Clerk A. Daytime somnolence: therapeutic approaches. Neurophysiol Clin 1993;23(1): 23-33.
115. Mullington J, Broughton R. Scheduled naps in the management of daytime sleepiness in narcolepsy-cataplexy. Sleep 1993;16(5):444-56.
116. Liu M, Thankachan S, Kaur S, Begum S, Blanco-Centurion C, Sakurai T, Yanagisawa M, Neve R, Shiromani PJ. 2008. Orexin (hypocretin) gene transferdiminishes narcoleptic sleep behavior in mice. Eur J Neurosci. 28, 1382-1393.
117. Arias-Carrion O, Murillo-Rodriguez E, Xu M, Blanco-Centurion C, Drucker-Colin R, Shiromani PJ. Transplant of hypocretin neurons into the pontine reticular formation: Preliminary results. Sleep 2004;27(8):1465-1470.